IDEXX Laboratories, Inc. (IDXX) Shares Bought by Victory Capital Management Inc.

Victory Capital Management Inc. grew its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 16.2% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,919 shares of the company’s stock after buying an additional 1,385 shares during the quarter. Victory Capital Management Inc.’s holdings in IDEXX Laboratories were worth $1,601,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in IDXX. Janney Montgomery Scott LLC lifted its holdings in shares of IDEXX Laboratories by 2.9% during the 1st quarter. Janney Montgomery Scott LLC now owns 3,130 shares of the company’s stock valued at $484,000 after buying an additional 87 shares during the period. Shell Asset Management Co. lifted its holdings in shares of IDEXX Laboratories by 3.4% during the 1st quarter. Shell Asset Management Co. now owns 5,088 shares of the company’s stock valued at $787,000 after buying an additional 165 shares during the period. Strs Ohio lifted its holdings in shares of IDEXX Laboratories by 9.5% during the 1st quarter. Strs Ohio now owns 5,888 shares of the company’s stock valued at $910,000 after buying an additional 512 shares during the period. DekaBank Deutsche Girozentrale lifted its holdings in shares of IDEXX Laboratories by 130.6% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 6,919 shares of the company’s stock valued at $1,111,000 after buying an additional 3,918 shares during the period. Finally, Suntrust Banks Inc. lifted its holdings in shares of IDEXX Laboratories by 21.5% during the 1st quarter. Suntrust Banks Inc. now owns 7,544 shares of the company’s stock valued at $1,164,000 after buying an additional 1,337 shares during the period. 87.73% of the stock is currently owned by hedge funds and other institutional investors.

Shares of IDEXX Laboratories, Inc. (IDXX) opened at 160.23 on Tuesday. The stock has a market cap of $13.98 billion, a price-to-earnings ratio of 55.12 and a beta of 0.49. The firm has a 50-day moving average price of $155.98 and a 200-day moving average price of $158.63. IDEXX Laboratories, Inc. has a 52 week low of $102.45 and a 52 week high of $173.01.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Tuesday, August 1st. The company reported $0.95 earnings per share for the quarter, topping analysts’ consensus estimates of $0.85 by $0.10. The business had revenue of $508.90 million during the quarter, compared to the consensus estimate of $502.44 million. IDEXX Laboratories had a net margin of 14.13% and a negative return on equity of 473.46%. The company’s revenue was up 9.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.74 earnings per share. On average, equities analysts anticipate that IDEXX Laboratories, Inc. will post $3.18 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This news story was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this news story on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this news story can be viewed at https://sportsperspectives.com/2017/09/12/idexx-laboratories-inc-idxx-shares-bought-by-victory-capital-management-inc.html.

Several equities analysts have recently weighed in on IDXX shares. Zacks Investment Research cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Tuesday, June 27th. Canaccord Genuity reissued a “buy” rating and set a $180.00 price target on shares of IDEXX Laboratories in a report on Tuesday, June 13th. Stifel Nicolaus reissued a “buy” rating and set a $185.00 price target on shares of IDEXX Laboratories in a report on Monday, August 21st. Finally, BidaskClub upgraded IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a research note on Friday, June 23rd. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $174.00.

In other IDEXX Laboratories news, Chairman Jonathan W. Ayers sold 58,000 shares of the company’s stock in a transaction dated Wednesday, August 16th. The shares were sold at an average price of $155.00, for a total value of $8,990,000.00. Following the completion of the transaction, the chairman now owns 1,043,034 shares in the company, valued at $161,670,270. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Jonathan W. Ayers sold 18,000 shares of the company’s stock in a transaction dated Monday, August 14th. The stock was sold at an average price of $154.91, for a total transaction of $2,788,380.00. Following the completion of the transaction, the chief executive officer now owns 1,043,034 shares of the company’s stock, valued at approximately $161,576,396.94. The disclosure for this sale can be found here. In the last quarter, insiders sold 151,734 shares of company stock valued at $23,436,626. Insiders own 2.77% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply